Results 271 to 280 of about 433,923 (290)

Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC)

Expert Opinion on Investigational Drugs, 2019
Daruka Mahadevan, Hani M. Babiker
exaly  

Gemcitabine resistance in pancreatic ductal adenocarcinoma

Drug Resistance Updates, 2015
Ziv Gil, Shorook Na'ara, Yoav Binenbaum
exaly  

B lymphocytes contribute to stromal reaction in pancreatic ductal adenocarcinoma

OncoImmunology, 2020
Paolo G Arcidiacono, Cristina Scielzo, Angelo A Manfredi   +2 more
exaly  

Activated Pancreatic Stellate Cells Sequester CD8+ T Cells to Reduce Their Infiltration of the Juxtatumoral Compartment of Pancreatic Ductal Adenocarcinoma

Gastroenterology, 2013
Hemant Kocher, Jun Wang, Alan G Ramsay
exaly  

Stratification of Pancreatic Ductal Adenocarcinomas Based on Tumor and Microenvironment Features

Gastroenterology, 2018
Laetitia Marisa, Maria Gomez Galdon, Pieter Demetter   +2 more
exaly  

HMGA1 correlates with advanced tumor grade and decreased survival in pancreatic ductal adenocarcinoma

Modern Pathology, 2009
Alexandra C Hristov, Linda M S Resar, Leslie Cope   +2 more
exaly  

Pancreatic Ductal Adenocarcinoma

2008
openaire   +2 more sources

Myeloid-derived macrophages and secreted HSP90α induce pancreatic ductal adenocarcinoma development

OncoImmunology, 2018
Kee Voon Chua, Tze-Sing Huang, Yi-Ming Shyr   +2 more
exaly  

BTN3A is a prognosis marker and a promising target for Vγ9Vδ2 T cells based-immunotherapy in pancreatic ductal adenocarcinoma (PDAC)

OncoImmunology, 2018
Mauro Modesti, Nelson Dusetti, Giuseppe Montalto   +2 more
exaly  

Necrotizing Pancreatitis Caused by Pancreatic Ductal Adenocarcinoma

Pancreas, 2001
N J, Zyromski, J, Haidenberg, M G, Sarr
openaire   +2 more sources